» Articles » PMID: 15572184

Cognitive Functioning in Schizophrenia and Bipolar Disorder: Comparison of Performance on the Repeatable Battery for the Assessment of Neuropsychological Status

Overview
Journal Psychiatry Res
Specialty Psychiatry
Date 2004 Dec 2
PMID 15572184
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Cognitive dysfunction is an important feature of schizophrenia and bipolar disorder. There is uncertainty about the relative magnitude of cognitive deficits in these disorders. We evaluated a total of 446 individuals: 229 with schizophrenia, 117 with bipolar disorder, and 100 controls without a history of psychiatric disorder. All participants were administered the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), a cognitive screening battery that evaluated immediate verbal memory, visuospatial/constructional abilities, attention, language, and delayed memory. A comparison of the three groups showed significant differences on the RBANS total score and all of the measured domains. In all of the comparisons, the schizophrenia group obtained the lowest scores, followed by the bipolar disorder group, and then the individuals without psychiatric disorder. In an analysis of covariance of RBANS total scores with the patient samples, the difference between schizophrenia and bipolar disorder remained significant after controlling for a range of demographic and clinical variables. Both schizophrenia and bipolar disorder are associated with significant cognitive impairments, but those in schizophrenia are more severe. Cognitive deficits may be an appropriate target of treatment interventions in these disorders.

Citing Articles

The repeatable battery for the assessment of neuropsychological status (RBANS) and substance use disorders: a systematic review.

Hoiland K, Raudeberg R, Egeland J Subst Abuse Treat Prev Policy. 2025; 20(1):12.

PMID: 40065390 PMC: 11895193. DOI: 10.1186/s13011-025-00640-2.


Association between the polymorphism and delayed memory in first-episode schizophrenic patients.

Zhu Z, Yin X, Cai Y, Jia N, Wang P, Qi Q Schizophr Res Cogn. 2024; 36:100304.

PMID: 38444400 PMC: 10912683. DOI: 10.1016/j.scog.2024.100304.


Efficacy of metacognitive training on symptom severity, neurocognition and social cognition in patients with schizophrenia: A single-blind randomized controlled trial.

Fekete Z, Vass E, Balajthy R, Tana U, Nagy A, Olah B Scand J Psychol. 2022; 63(4):321-333.

PMID: 35388496 PMC: 9544200. DOI: 10.1111/sjop.12811.


Acute Inositol-Stabilized Arginine Silicate Improves Cognitive Outcomes in Healthy Adults.

Gills J, Campitelli A, Jones M, Paulson S, Myers J, Madero E Nutrients. 2021; 13(12).

PMID: 34959823 PMC: 8703995. DOI: 10.3390/nu13124272.


Characteristics of Dimensional Psychopathology in Suicidal Patients With Major Psychiatric Disorders and Its Association With the Length of Hospital Stay: Algorithm Validation Study.

Lee D, Park J, Noh J, Roh H, Ha J, Lee E JMIR Ment Health. 2021; 8(9):e30827.

PMID: 34477555 PMC: 8449292. DOI: 10.2196/30827.